Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.
Carvedilol was granted FDA approval on 14 September 1995.
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
- Conditions
- Hypertension
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT00552708
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
- Conditions
- Hypertension
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT00549510
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure
- Conditions
- Chronic Heart Failure
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Centro Cardiologico Monzino
- Target Recruit Count
- 60
- Registration Number
- NCT00517725
- Locations
- 🇮🇹
Centro Cardiologico Monzino, University of Milan, Milan, Italy
Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT00508365
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT00496834
Danish Carvedilol Study in Portal Hypertension
- Conditions
- CirrhosisPortal Hypertension
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2009-08-10
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00493480
- Locations
- 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark
The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients
- Conditions
- Abdominal ObesityHypertension
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- St. Paul Heart Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT00459056
- Locations
- 🇺🇸
St. Paul Heart Clinic, St. Paul, Minnesota, United States
A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT00444834
- Locations
- 🇩🇰
Site 02, Esbjerg, Denmark
🇩🇰Site 01, Frederiksberg, Denmark
"The Evaluation of Stimulant Withdrawal"
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Aaron J. Janowsky
- Registration Number
- NCT00442923
- Locations
- 🇺🇸
US Veterans Hospital, Portland, Oregon, United States
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
- Conditions
- HypertensionDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 14
- Registration Number
- NCT00430040
- Locations
- 🇺🇸
Diabetes - Endocrinology Center of Western New York, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.